When:Tuesday February 24, 2015from 1:00 PM to 6:00PM EST

Where:Cambridge Marriott, 50 Broadway, Cambridge, MASalon IV Ballroom, located on the 2nd floor

Contact:Chao Li - Chao.Li@WuXiAppTec.com

TIME SPEAKER TOPIC

1:00 - 2:00 pm Guest Registration

2:00 pm Ribbon Cutting Ceremony

2:15 pm Dennis Benzan RemarksDongbai Ye

2:30 pm Susan Windham-Bannister Introduction

2:40 pm Josh Boger Keynote Speech

3:00 pm Alexis Borisy Keynote Speech

3:20 pm Robert Urban Keynote Speech

3:45 pm David Altshuler Scott BillerJohn Bishop Panel DiscussionJorge CondeNick Leschly

4:30 - 6:00 pm Reception

WuXi AppTec Inc. is a leading platform company serving the life sciences industry. With its 9,000+ scientists across 16 global campuses, WuXi enables R&D innovation of biopharmaceutical and medical device companies, from start-ups to the largest multinationals. Located at 222 Third Street, Cambridge, the office will enable greater access to WuXi's leading open access R&D capability and technology platform.

The reception will bring together key leaders in life sciences in an open forum to foster innovation and collaboration. Titled "Massachusetts: the Convergence of Science, Capital & Innovation" and hosted by the Cambridge office head, Dr. Richard Soll, the forum will provide learning and networking opportunities with a glimpse of some of the hottest local sciences.

Welcome

Endocrinologist and human geneticist David Altshuler is Executive Vice-President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. He was previously a founding Core Member, Deputy Director and Chief Academic Officer of the Broad Institute at Harvard and MIT, and a physician at Massachusetts General Hospital.

David was a leader of the SNP Consortium, HapMap and 1,000 Genome Projects, and discovered over 100 gene variants associated with type 2 diabetes and other common diseases.

He is a member of the Institute of Medicine, American Academy of Arts and Sciences, and was named a Champion of Change by the White House for his leadership in creating and leading the Global Alliance for Genomic and Health.

Vice Mayor of Cambridge, MA. Son of immigrant parents, Dennis A. Benzan was elected as the first Latino to serve on the City Council for Cambridge, MA, and voted unanimously as the Vice Mayor in November of 2013. His strongest initiatives include developing a homegrown workforce for a booming innovation economy in Cambridge by developing Science, Technology, Engineering, Arts, and Mathematics (STEAM) workforce training programs for the young and old.

Dennis holds a JD from Roger Williams School of Law and a degree in political science from Howard University. Dennis is the father of seven-year-old twins, India and Matteo, and the husband of Tanya Bacci-Benzan.

Dr. Biller joined Agios as chief scientific officer in September 2010, with more than 25 years of drug discovery and development experience. Most recently, from 2003 to September 2010, he was vice president and head of global discovery chemistry at the Novartis Institutes for Biomedical Research (NIBR). Prior to that, Dr. Biller held the positions of vice president, pharmaceutical candidate optimization at the Bristol Myers Squibb (BMS) Pharma-ceutical Research Institute and executive director of drug discovery chemistry for the BMS research site in Lawrenceville, NJ. Among his other key leadership positions at BMS, Dr. Biller was the executive director of metabolic diseases chemistry. He contributed to robust pipelines at both BMS and Novartis, culminating in two medicines launched worldwide (Onglyza® for the treatment of Type 2 diabetes and Juxtapid® for familial hyper-cholestrolemia) and three additional drugs reaching Phase 3 clinical development. Dr. Biller earned a B.S. in chemistry at MIT, a Ph.D. in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University in natural product synthesis.

Dr. John Bishop is Senior Vice President of Pharmaceutical Sciences at Momenta Pharmaceuticals, responsible for the CMC activities of Momenta’s programs in complex generics, Follow-on Biologics (FOBs), and new drugs. Prior to Momenta, he held positions of increasing responsibility at Alcon Laboratories, where he was co-inventor of the anti-glaucoma drug Travatan®; DuPont Merck Pharmaceuticals; and Millennium Pharmaceuticals. Dr. Bishop received a B.S. in Chemistry and German from Tufts University, a Ph.D. in Organic Chemistry from the University of California, Berkeley, and an MBA from Northeastern University.

Dr. Joshua Boger is the founder of Vertex Pharmaceuticals Incorporated and the Executive Chairman of Alkeus Pharmaceuticals, Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories where he headed both the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology & Inflammation. He is a pioneer in structure-based rational drug design.

Dr. Boger holds a BA in Chemistry and Philosophy from Wesleyan University, and a master's and doctorate degrees in Chemistry from Harvard University. He is married to Amy Boger, M.D., F.A.A.P., a professional ceramic artist, and they have three sons.

(Continued on next page)

Dr. David Altshuler

Dr. Scott Biller

Dr. John Bishop

Dr. Joshua Boger

WuXi AppTec Scientific Forum & Reception Speakers’ Biographies

Mr. Dennis Benzan

Mr. Alexis Borisy

Alexis Borisy is a Partner at Third Rock Ventures, where he focuses on the formation, development and strategy of new companies. He’s co-founded, served as interim CEO and is currently Chairman of the Board of both Foundation Medicine and Warp Drive Bio, and co-founded and served as interim CEO of Blueprint Medicines. He is also a Board Member of Editas Medicine and Revolution Medicine.

CFO and Chief Product Officer, Syros Pharmaceuticals. Jorge Conde is a biotechnology entrepreneur with over 15 years of experience. In June 2014, he was appointed CFO and Chief Product Officer of Syros Pharmaceuticals. Jorge leads the platform strategy for Syros’ novel gene regulation technology and manages the overall finances for the company. Prior to joining Syros, Jorge co-founded Knome, a human genome interpretation company, with George Church, Professor of Genetics at Harvard Medical School. Jorge formerly worked as a biotechnology invest-ment banker at Morgan Stanley. He serves as an Overseer for the Boston Museum of Science. Jorge has been named one of the top 35 young innovators in the world by the MIT Technology Review. He holds an M.B.A. from Harvard Business School, a Master of Science degree from the Harvard-MIT Division of Health Sciences and Technology (HST), and a Bachelor's degree in Biology from The Johns Hopkins University.

Nick Leschly has served as president and chief executive officer of Bluebird Bio since March 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock's portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs. He received his B.S. in molecular biology from Princeton University and his M.B.A. from Wharton Business School. He currently serves as a member of the Biotechnology Industry Organization board.

Dr. Robert Urban leads Johnson & Johnson’s Boston Innovation Center. Johnson & Johnson Innovation Centers are home to investment teams that work closely with entrepreneurs to advance products and technology up to proof-of-concept across the pharmaceuticals, medical device & diagnostic and consumer sectors. Their investments focus on people and programs that have the potential to not just advance healthcare, but to transform it. Located in Boston, Menlo Park, London and Shanghai, the J&J Innovation Centers seek to simplify and expedite the transformation of discoveries into healthcare products that improve lives across the world.

Dr. Susan Windham-Bannister is an internationally recognized innovation expert and the founding President and CEO of the Massachusetts Life Sciences Center (MLSC). As founding President and CEO, Dr. Windham-Bannister has been responsible for the overall implementation of the Life Sciences Initiative, including formulating the investment strategy, creating a brand, staffing the organization, developing policies and procedures and building national and international partnerships. Before assuming her role at the MLSC, Dr. Windham-Bannister co-founded Abt Bio-Pharma Solutions (ABS), co-authored 2 books and wrote numerous articles on competition in today’s health care marketplace.

Dr. Windham-Bannister received a B.A. from Wellesley College, a doctorate in health policy and management from the Florence Heller School at Brandeis University, and a Doctor of Science from Worcester Polytechnic Institute in 2012 (honoris causa). She completed her doctoral work under a fellowship from the Ford Foundation and was also a post-doctoral fellow at Harvard University’s John F. Kennedy School

Counselor Dongbai Ye graduated from Shizuoka University in Japan with a master's degree in semiconductor engineering. He has served in China's Ministry of Science and Technology for nearly 30 years, with rich experience and comprehensive understanding of China's science and technology development history and policy making, especially in the field of international cooperation. Mr. Ye also served as the Vice Mayor of Anshan City in Liaoning Province. Before his assignment in New York, Mr. Ye was the Minister-Counselor for science and Technology in the Embassy of the P. R. China in Japan.

Mr. Nick Leschly

Dr. Robert Urban

Dr. Susan Wind-ham-Bannister

Mr. Dongbai Ye

WuXi AppTec Scientific Forum & Reception Speakers’ Biographies

Mr. Jorge Conde